MedPath

Kim's Eye Hospital

Kim's Eye Hospital logo
🇰🇷South Korea
Ownership
Private
Established
1962-01-01
Employees
11
Market Cap
-
Website
https://kimeye.com

Clinical Trials

8

Active:0
Completed:6

Trial Phases

2 Phases

Phase 4:4
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 4
4 (80.0%)
Not Applicable
1 (20.0%)

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Phase 4
Recruiting
Conditions
Age-related Macular Degeneration (ARMD)
Interventions
First Posted Date
2024-11-12
Last Posted Date
2024-11-12
Lead Sponsor
Kim's Eye Hospital
Target Recruit Count
40
Registration Number
NCT06683950
Locations
🇰🇷

Kim's Eye Hospital, Seoul, Korea, Republic of

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed
Conditions
Polypoidal Choroidal Vasculopathy
Choroidal Neovascularization
Age-Related Macular Degeneration
Interventions
First Posted Date
2022-12-23
Last Posted Date
2023-12-14
Lead Sponsor
Kim's Eye Hospital
Target Recruit Count
135
Registration Number
NCT05662943
Locations
🇰🇷

Jae Hui Kim, Seoul, Korea, Republic of

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

Phase 4
Completed
Conditions
Pachychoroid Neovasculopathy
Interventions
Drug: Three monthly injections of intravitreal aflibercept
First Posted Date
2022-12-22
Last Posted Date
2025-05-31
Lead Sponsor
Kim's Eye Hospital
Target Recruit Count
30
Registration Number
NCT05662410
Locations
🇰🇷

Jae Hui Kim, Seoul, Korea, Republic of

Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion

Completed
Conditions
Age-related Macular Degeneration
First Posted Date
2021-04-08
Last Posted Date
2021-04-08
Lead Sponsor
Kim's Eye Hospital
Target Recruit Count
512
Registration Number
NCT04836143
Locations
🇰🇷

Jae Hui Kim, Seoul, Korea, Republic of

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Phase 4
Conditions
Retinal Angiomatous Proliferation
Interventions
First Posted Date
2020-12-07
Last Posted Date
2022-08-22
Lead Sponsor
Kim's Eye Hospital
Target Recruit Count
30
Registration Number
NCT04655482
Locations
🇰🇷

Jae Hui Kim, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.